Metabolic (bariatric) surgery is an effective long-term intervention for obesity-related T2DM, while modern injectable pharmacotherapies, including glucagon-like peptide-1 receptor agonists, have become increasingly popular. This evidence concerns the gene GLP1R and obesity disorder.